Study Finds Delays in Bladder Cancer Chemotherapy
A retrospective Columbia University analysis found more than a third of muscle-invasive bladder cancer patients waited over 60 days to start neoadjuvant chemotherapy.
Updated on Nov. 7, 2026 in Cancer
Researchers at Columbia University reported on October 16, 2026, that 35% of patients with muscle-invasive bladder cancer waited more than 60 days for neoadjuvant chemotherapy. The retrospective study of 117 patients treated between 2014 and 2024 found a median delay of 47 days from pathologic diagnosis to treatment.
Why it matters
Neoadjuvant chemotherapy is given before surgery to shrink tumors and improve outcomes, so prolonged waits could affect treatment effectiveness. The findings point to care-coordination issues, which may be addressable by health systems.
The retrospective cohort of 117 patients showed 41 cases (35%) with delays beyond 60 days, with imaging or procedures responsible for 29.2% and second opinions or care transfers for 22.0%. The causes of 17.1% of delays remain unidentified.
The players
Columbia University Irving Medical Center
A major academic medical center in New York City affiliated with Columbia University, where the retrospective study was conducted.
American Society of Clinical Oncology (ASCO)
A leading professional organization of oncologists that hosts the annual ASCO Quality Care Symposium, where the findings were presented.
The details
Investigators identified patients with muscle-invasive bladder cancer through electronic health records and determined reasons for delay by chart review. Black patients showed a higher likelihood of delay compared with White patients, though the association was not statistically significant.
Timeline
2014-2024: Patients treated with neoadjuvant chemotherapy were identified for the study.
October 16-17, 2026: Findings were presented at the 2026 ASCO Quality Care Symposium in Boston.
Big Picture
Recent 2026 guideline updates are moving newer agents into the neoadjuvant setting for muscle-invasive bladder cancer, which makes the timing of treatment initiation increasingly consequential. This study examines whether that treatment sequence is being delivered on schedule in practice.
Patients diagnosed with muscle-invasive bladder cancer may benefit from asking their care team about the expected timeline to neoadjuvant chemotherapy. Second opinions and transfers of care were among the common causes of delay identified in the study.
The takeaway
Timely coordination between imaging, second opinions, and treatment planning may help patients with muscle-invasive bladder cancer begin chemotherapy sooner. Patients can ask their care team to map out each step before treatment begins.
Further reading
Explore more on Cancer coverage for context on treatment timing and care delivery.
Source note: This article includes information reported by Oncnursingnews.
